Drugs / CD19 or CD20 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02846584 | Jul 2016 → Dec 2019 | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma | Southwest Hospital, China | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 or CD20 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02846584 ↗ |
| Modality | Cell therapy | “anti-CD20 CAR T cells has been used in the treatment of relapsed/refractory DLBCL” NCT02846584 ↗ |
| Route | Intravenous | “are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells” NCT02846584 ↗ |